Introduction
============

Nanomaterials refer to those with sizes ranging from 1 to 100 nm in at least one dimension. Nanosized particles possess a number of superior physicochemical properties compared with the same material fabricated in a conventional manner, including high thermal and chemical stability, hydrophobicity, heat and electrical insulation, resistance to oxidation, good biocompatibility and minimal immunogenicity, which make them as attractive and promising candidates for a wide range of advanced applications ([@ref-18]; [@ref-24]). Silica is the most frequently used material to create nanoparticles due to its higher abundance on earth and thus a relatively low-cost for preparation. It is estimated that approximately one million tons of synthetic amorphous silica nanoparticles (SiNPs) may be produced per year worldwide to act as additives to cosmetics, drug tablets, paints, varnishes, food or deliveries for gene, protein and drugs ([@ref-10]). The widespread application of amorphous SiNPs leads to frequent human exposure and therefore its safety is of high concern. Although amorphous SiNPs are supposedly non-carcinogenic for humans according to the classification of the International Agency for Research of Cancer (Group 3), recently published studies proposed long-term exposure of amorphous SiNPs may induce cell malignant transformation and tumorigenesis ([@ref-9]; [@ref-12]). Therefore, how to early diagnose and prevent the development of amorphous SiNPs-induced cancer may be an underlying challenge that needs to be solved. This resulted in the requirements for understanding the molecular mechanisms of the tumor-promoting effects.

In a recent study, [@ref-12] used a microarray analysis to investigate the genes significantly changed by amorphous SiNPs in human lung epithelial cells and found amorphous SiNPs may trigger tumorigenesis by influencing 821 significant differentially expressed genes (DEGs) (five upregulated and 816 downregulated) to regulate oxidative stress, oxidative phosphorylation, DNA damage, p53 and MAPK signaling pathways. However, the related mechanism leading to the development of cancer by amorphous SiNPs still remains unclear. In present study, we aim to re-analyze the microarray data established by [@ref-12] via different bioinformatic approaches: the DEGs were identified by the linear models for microarray data (LIMMA) method, but not random variance model; Compared with study of [@ref-12], a strict threshold was used for screening DEGs (\|logFC(fold change)\| \> 2 & *P* \< 0.05 vs FC \> 2 & *P* \< 0.05), which may be beneficial to obtain more crucial and verifiable genes associated with amorphous SiNPs; the whole protein--protein interaction (PPI) network for all DEGs were established, but not signal-net analysis network PPI; In addition, the miRNA-target genes interaction network was also analyzed to explore the regulatory mechanisms of DEGs and then screen key upstream targets for amorphous SiNPs, which had not previously been performed.

Materials and Methods
=====================

Microarray data
---------------

The microarray data were extracted from the gene expression omnibus (GEO) database (<http://www.ncbi.nlm.nih.gov/geo/>) under accession number [GSE82062](GSE82062) ([@ref-12]), in which three repeats of human lung epithelial cells, Beas-2B continuously exposed to five μg/mL amorphous SiNPs for 40 passages (BeasSiNPs-P40 group; [Supplemental Information 1.1](#supp-1){ref-type="supplementary-material"}, [1.2](#supp-2){ref-type="supplementary-material"}, [1.3](#supp-3){ref-type="supplementary-material"}) and three repeats of passage-matched control Beas-2B cells (Beas-P40 group) ([Supplemental Information 1.4](#supp-1){ref-type="supplementary-material"}, [1.5](#supp-5){ref-type="supplementary-material"}, [1.6](#supp-6){ref-type="supplementary-material"}) were available for the analysis.

Data normalization and DEGs identification
------------------------------------------

The raw data (CEL files) of [GSE82062](GSE82062) were downloaded from the Affymetrix Human Transcriptome Array 2.0 platform GPL17586. The raw data were preprocessed, background-corrected and summarized using robust multichip average algorithm ([@ref-14]) in the "affy" package of Bioconductor R (v3.4.1; <http://www.bioconductor.org/packages/release/bioc/html/affy.html>). The DEGs between BeasSiNPs-P40 and Beas-P40 groups were identified using the LIMMA method ([@ref-27]) in the Bioconductor R package (v3.4.1; <http://www.bioconductor.org/packages/release/bioc/html/limma.html>). The *t*-test was used to identify the *P*-value and FC was calculated. Genes were considered to be differentially expressed with the threshold value setting to \|logFC\| \> 2 and *P* \< 0.05.

To determine the specificity of DEGs between BeasSiNPs-P40 and Beas-P40 groups, bidirectional hierarchical clustering analysis with Euclidean distance ([@ref-30]) was performed for the top 50 DEGs using the pheatmap package in R (version 1.0.8; [@ref-39]).

PPI network construction and module analysis
--------------------------------------------

The DEGs were imported into STRING database (v10.0; Search Tool for the Retrieval of Interacting Genes; <https://string-db.org/>) ([@ref-31]) to obtain the PPI data. The PPI network was constructed and visualized using Cytoscape software (v2.8; [www.cytoscape.org/](www.cytoscape.org/)) ([@ref-17]). The hub genes with more interactions with other partners (degree) were selected and plotted with ggplot2 in R package (v3.4.1; [@ref-40]).

Furthermore, the Molecular Complex Detection (MCODE) plugin of Cytoscape software was also employed to identify functionally related and highly interconnected clusters from the PPI network with degree cutoff of 6, node score cutoff of 0.2, *k*-core of 5 and maximum depth of 100 (ftp://ftp.mshri.on.ca/pub/BIND/Tools/MCODE) ([@ref-1]). Sub-modules were defined to be significant with MCODE score ≥ 4 and nodes ≥ 6.

miRNA-target genes interaction prediction
-----------------------------------------

Because there were some pre-miRNAs included in the DEGs, the pre-miRNA--mRNA interaction was also investigated to explore the potential regulatory mechanisms of mRNAs. mRNA targets of differentially expressed miRNAs (DE-miRNAs) were predicted using the miRWalk database (v2.0; <http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/>) ([@ref-5]), which were then overlapped with the DEGs to obtain DE-miRNA--DEGs interaction relationships. Then, the DE-miRNA--DEG interaction network was constructed and visualized using Cytoscape software ([@ref-17]).

Function enrichment analysis
----------------------------

Gene ontology (GO) biological process terms, Kyoto Encyclopedia of Genes and Genomes (KEGG), and BioCarta pathways were also enriched for all DEGs, DEGs in PPI and miRNA--DEG interaction networks by the Database for Annotation, Visualization and Integrated Discovery (DAVID) online tool (v6.8; <http://david.abcc.ncifcrf.gov>) ([@ref-3]). *P*-value \< 0.05 was chosen as the threshold value for functional enrichment analyses.

Results
=======

Identification of DEGs
----------------------

After preprocessing and data normalization (gene expression in all samples are shown in [Supplemental Information 2](#supp-7){ref-type="supplementary-material"}), DEGs between BeasSiNPs-P40 and Beas-P40 groups were identified by the LIMMA method. As a result, 323 genes were considered to be differentially expressed due to exceeding the difference threshold (\|logFC\| \> 2 and *P* \< 0.05), including 280 downregulated (containing 12 pre-miRNAs) and 43 upregulated genes (containing 29 pre-miRNAs) ([Fig. 1](#fig-1){ref-type="fig"}), which was fewer than the study results of [@ref-12]. All the DEGs are listed in in [Supplemental Information 3](#supp-8){ref-type="supplementary-material"}.

![Heat map of differentially expressed genes identified between human lung epithelial cell Beas-2B exposed to amorphous silica nanoparticles or not.\
High level of expression was indicated as red and low level was in green. Heatmap was established based on normalized expression values of significantly changed mRNAs. The expression values are depicted in line with the color scale. The intensity increases from green to red. Each column represents one sample, and each row indicates a transcript.](peerj-07-6455-g001){#fig-1}

Function enrichment analysis of DEGs
------------------------------------

The above differential genes were subjected to the online tool DAVID for function enrichment analysis. As a result, 49 GO biological process terms were enriched for downregulated DEGs, including response to reactive oxygen species (ROS) (i.e., superoxide dismutase 1 (SOD1)). Only two GO biological process terms were enriched for upregulated DEGs, mainly involving in protein translation (i.e., eukaryotic translation initiation factor 4 gamma 2 (EIF4G2); poly (A) binding protein cytoplasmic 1 (PABPC1)) ([Table 1](#table-1){ref-type="table"}).
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###### Gene ontology (GO) biological process terms analysis for all differentially expressed genes.

![](peerj-07-6455-g005)

![](peerj-07-6455-g006)

                                                                                                         Term                                            *P*-value                                                                                                            Genes
  ------------------------------------------------------------------------------------------------------ ----------------------------------------------- -------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Down                                                                                                   GO:0006334∼nucleosome assembly                  2.32E-16                                                                                                             HIST1H2BB, HIST1H3J, HIST1H4L, HIST1H1E, HIST1H1C, HIST1H2BF, HIST1H2BO, HIST1H2BK, HIST1H4B, HIST1H2BI, HIST1H3A, HIST1H4E, HIST1H3B, HIST1H4C, HIST1H3D, HIST1H4D, HIST1H3F
                                                                                                         GO:0051290∼protein heterotetramerization        5.54E-15                                                                                                             HIST1H3J, HIST1H4L, HIST1H4B, XRCC6, HIST1H3A, HIST1H3B, HIST1H4E, HIST1H3D, HIST1H4C, HIST1H4D, HIST1H3F, ANXA2
  GO:0032200∼telomere organization                                                                       1.51E-13                                        HIST1H3J, HIST1H4L, HIST1H4B, HIST1H3A, HIST1H3B, HIST1H4E, HIST1H3D, HIST1H4C, HIST1H4D, HIST1H3F                   
  GO:0045815∼positive regulation of gene expression, epigenetic                                          5.82E-13                                        HIST1H3J, HIST1H4L, POLR2L, POLR2K, HIST1H4B, HIST1H3A, HIST1H3B, HIST1H4E, HIST1H3D, HIST1H4C, HIST1H4D, HIST1H3F   
  GO:0006335∼DNA replication-dependent nucleosome assembly                                               8.76E-13                                        HIST1H3J, HIST1H4L, HIST1H4B, HIST1H3A, HIST1H3B, HIST1H4E, HIST1H3D, HIST1H4C, HIST1H4D, HIST1H3F                   
  GO:0000183∼chromatin silencing at rDNA                                                                 3.77E-12                                        HIST1H3J, HIST1H4L, HIST1H4B, HIST1H3A, HIST1H3B, HIST1H4E, HIST1H3D, HIST1H4C, HIST1H4D, HIST1H3F                   
  GO:0045814∼negative regulation of gene expression, epigenetic                                          7.03E-11                                        HIST1H3J, HIST1H4L, HIST1H4B, HIST1H3A, HIST1H3B, HIST1H4E, HIST1H3D, HIST1H4C, HIST1H4D, HIST1H3F                   
  GO:0031047∼gene silencing by RNA                                                                       4.04E-10                                        HIST1H3J, HIST1H4L, POLR2L, POLR2K, HIST1H4B, HIST1H3A, HIST1H3B, HIST1H4E, HIST1H3D, HIST1H4C, HIST1H4D, HIST1H3F   
  GO:0044267∼cellular protein metabolic process                                                          7.84E-10                                        HIST1H3J, HIST1H4L, HIST1H4B, TGFBI, HIST1H3A, HIST1H3B, HIST1H4E, HIST1H3D, HIST1H4C, HIST1H4D, HIST1H3F, B2M       
  GO:0006614∼SRP-dependent cotranslational protein targeting to membrane                                 2.29E-08                                        RPS28, RPS29, RPL41, RPS15, RPL26, RPS13, RPS15A, RPS4Y1, RPL24, RPS5                                                
  GO:0098609∼cell-cell adhesion                                                                          7.12E-08                                        HIST1H3J, CHMP5, EEF2, RPL24, PDLIM1, SFN, ANXA2, KRT18, HIST1H3A, HIST1H3B, HIST1H3D, CNN2, HIST1H3F, ENO1          
  GO:0019083∼viral transcription                                                                         1.06E-07                                        RPS28, RPS29, RPL41, RPS15, RPL26, RPS13, RPS15A, RPS4Y1, RPL24, RPS5                                                
  GO:0000184∼nuclear-transcribed mRNA catabolic process, nonsense-mediated decay                         1.80E-07                                        RPS28, RPS29, RPL41, RPS15, RPL26, RPS13, RPS15A, RPS4Y1, RPL24, RPS5                                                
  GO:0006413∼translational initiation                                                                    5.98E-07                                        RPS28, RPS29, RPL41, RPS15, RPL26, RPS13, RPS15A, RPS4Y1, RPL24, RPS5                                                
  GO:0060968∼regulation of gene silencing                                                                7.87E-07                                        HIST1H3J, HIST1H3A, HIST1H3B, HIST1H3D, HIST1H3F                                                                     
  GO:0006364∼rRNA processing                                                                             3.14E-06                                        RPS28, RPS29, RPL41, RRP36, RPS15, RPL26, RPS13, RPS15A, RPS4Y1, RPL24, RPS5                                         
  GO:0006303∼double-strand break repair via nonhomologous end joining                                    5.72E-06                                        HIST1H4L, HIST1H4B, XRCC6, HIST1H4E, BABAM1, HIST1H4C, HIST1H4D                                                      
  GO:0045653∼negative regulation of megakaryocyte differentiation                                        7.02E-06                                        HIST1H4L, HIST1H4B, HIST1H4E, HIST1H4C, HIST1H4D                                                                     
  GO:0034080∼CENP-A containing nucleosome assembly                                                       1.33E-05                                        HIST1H4L, HIST1H4B, HIST1H4E, CENPW, HIST1H4C, HIST1H4D                                                              
  GO:0006412∼translation                                                                                 1.37E-05                                        RPS28, RPS29, RPL41, RPS15, RPL26, RPS13, RPS15A, RPS4Y1, RPL24, MRPS7, RPS5                                         
  GO:0006342∼chromatin silencing                                                                         1.67E-05                                        HIST1H2AB, HIST2H2AB, HIST2H2AA4, HIST2H2AC, HIST1H2AE, HIST1H2AM                                                    
  GO:0016233∼telomere capping                                                                            1.98E-05                                        HIST1H4L, HIST1H4B, HIST1H4E, HIST1H4C, HIST1H4D                                                                     
  GO:0006336∼DNA replication-independent nucleosome assembly                                             3.28E-05                                        HIST1H4L, HIST1H4B, HIST1H4E, HIST1H4C, HIST1H4D                                                                     
  GO:0006352∼DNA-templated transcription, initiation                                                     1.22E-04                                        HIST1H4L, HIST1H4B, HIST1H4E, HIST1H4C, HIST1H4D                                                                     
  GO:1904837∼beta-catenin-TCF complex assembly                                                           2.47E-04                                        HIST1H4L, HIST1H4B, HIST1H4E, HIST1H4C, HIST1H4D                                                                     
  GO:0000028∼ribosomal small subunit assembly                                                            3.17E-04                                        RPS28, RPS15, MRPS7, RPS5                                                                                            
  GO:0006123∼mitochondrial electron transport, cytochrome c to oxygen                                    3.71E-04                                        COX7B, COX8A, COX6B1, COX6A1                                                                                         
  GO:1902600∼hydrogen ion transmembrane transport                                                        9.45E-04                                        UQCR10, COX7B, COX8A, COX6B1, COX6A1                                                                                 
  GO:0043154∼negative regulation of cysteine-type endopeptidase activity involved in apoptotic process   1.50E-03                                        PRDX5, SFN, THBS1, IFI6, DHCR24                                                                                      
  GO:0019731∼antibacterial humoral response                                                              3.81E-03                                        HIST1H2BK, HIST1H2BF, HIST1H2BI, B2M                                                                                 
  GO:0042274∼ribosomal small subunit biogenesis                                                          5.69E-03                                        RPS28, RRP36, RPS15                                                                                                  
  GO:0002576∼platelet degranulation                                                                      6.37E-03                                        PSAP, THBS1, SOD1, SRGN, FN1                                                                                         
  GO:0002227∼innate immune response in mucosa                                                            1.36E-02                                        HIST1H2BK, HIST1H2BF, HIST1H2BI                                                                                      
  GO:0043086∼negative regulation of catalytic activity                                                   1.66E-02                                        OAZ1, NQO1, ANXA2, ANXA2P2                                                                                           
  GO:0050434∼positive regulation of viral transcription                                                  1.81E-02                                        POLR2L, POLR2K, SUPT4H1                                                                                              
  GO:0050830∼defense response to Gram-positive bacterium                                                 2.30E-02                                        HIST1H2BK, HIST1H2BF, HIST1H2BI, B2M                                                                                 
  GO:0006368∼transcription elongation from RNA polymerase II promoter                                    2.37E-02                                        POLR2L, POLR2K, ELOF1, SUPT4H1                                                                                       
  GO:0033490∼cholesterol biosynthetic process via lathosterol                                            2.83E-03                                        DHCR7, DHCR24                                                                                                        
  GO:0033489∼cholesterol biosynthetic process via desmosterol                                            2.83E-02                                        DHCR7, DHCR24                                                                                                        
  GO:0007568∼aging                                                                                       3.07E-02                                        CCL2, EEF2, SOD1, NQO1, APEX1                                                                                        
  GO:0000302∼response to reactive oxygen species                                                         3.16E-02                                        TXN, PRDX5, SOD1                                                                                                     
  GO:0001895∼retina homeostasis                                                                          3.31E-02                                        ACTG1, SOD1, B2M                                                                                                     
  GO:0045471∼response to ethanol                                                                         3.94E-02                                        CCL2, EEF2, SOD1, NQO1                                                                                               
  GO:0006356∼regulation of transcription from RNA polymerase I promoter                                  4.21E-02                                        POLR2L, POLR2K                                                                                                       
  GO:0098532∼histone H3-K27 trimethylation                                                               4.21E-02                                        HIST1H1E, HIST1H1C                                                                                                   
  GO:0007596∼blood coagulation                                                                           4.30E-02                                        HIST1H3J, HIST1H3A, HIST1H3B, HIST1H3D, HIST1H3F                                                                     
  GO:0009615∼response to virus                                                                           4.43E-02                                        IFITM2, IFITM3, RPS15A, ENO1                                                                                         
  GO:0043066∼negative regulation of apoptotic process                                                    4.48E-02                                        KRT18, PLK2, PLK1, TMBIM4, PRDX5, THBS1, NQO1, DHCR24                                                                
  GO:1900121∼negative regulation of receptor binding                                                     4.90E-02                                        ANXA2, B2M                                                                                                           
  Up                                                                                                     GO:0045727∼positive regulation of translation   1.57E-02                                                                                                             EIF4G2, PABPC1
  GO:0006413∼translational initiation                                                                    4.01E-02                                        EIF4G2, PABPC1                                                                                                       

Kyoto Encyclopedia of Genes and Genomes pathway analyses were also performed by DAVID software. In line with the GO terms, the downregulated DEGs were predicted to participate in oxidative stress related metabolism pathways, such as oxidative phosphorylation (i.e., ATP5H, ATP synthase, H+ transporting, mitochondrial F0 complex, subunit D), while upregulated DEGs were enriched for Regulation of eIF4e and p70 S6 Kinase (i.e., EIF4G2, PABPC1) ([Table 2](#table-2){ref-type="table"}).

10.7717/peerj.6455/table-2

###### KEGG pathway enrichment analysis for all differentially expressed genes.

![](peerj-07-6455-g007)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                        Term                                                   *P*-value                                                                                                                                                                                                                      Genes
  ----------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Down                                                  hsa05322: Systemic lupus erythematosus                 2.06E-16                                                                                                                                                                                                                       HIST1H2AB, HIST1H2BB, HIST1H3J, HIST1H4L, HIST2H2AA4, HIST1H2BF, HIST1H2AE, HIST1H2BO, HIST2H2AB, HIST1H2BK, HIST1H4B, HIST2H2AC, HIST1H2BI, HIST1H3A, HIST1H4E, HIST1H3B, HIST1H3D, HIST1H4C, HIST1H4D, HIST1H3F, HIST1H2AM

  hsa05034: Alcoholism                                  5.44E-14                                               HIST1H2AB, HIST1H2BB, HIST1H3J, HIST1H4L, HIST2H2AA4, HIST1H2BF, HIST1H2AE, HIST1H2BO, HIST2H2AB, HIST1H2BK, HIST1H4B, HIST2H2AC, HIST1H2BI, HIST1H3A, HIST1H4E, HIST1H3B, HIST1H3D, HIST1H4C, HIST1H4D, HIST1H3F, HIST1H2AM   

  hsa03010: Ribosome                                    9.39E-06                                               RPS28, RPS29, RPL41, RPS15, RPL26, RPS13, RPS15A, RPS4Y1, RPL24, MRPS7, RPS5                                                                                                                                                   

  hsa05016: Huntington's disease                        1.80E-04                                               UQCR10, NDUFS5, POLR2L, POLR2K, COX7B, COX8A, COX6B1, COX6A1, SOD1, NDUFA1, ATP5H                                                                                                                                              

  hsa00190: Oxidative phosphorylation                   3.14E-04                                               UQCR10, NDUFS5, ATP6V0E1, COX7B, COX8A, COX6B1, COX6A1, NDUFA1, ATP5H                                                                                                                                                          

  hsa05203: Viral carcinogenesis                        1.32E-03                                               HIST1H2BO, HIST1H2BB, HIST1H4L, HIST1H2BK, HIST1H2BF, HIST1H4B, HIST1H2BI, HIST1H4E, HIST1H4C, HIST1H4D                                                                                                                        

  hsa05010: Alzheimer's disease                         1.47E-03                                               UQCR10, NDUFS5, COX7B, COX8A, COX6B1, COX6A1, PSENEN, NDUFA1, ATP5H                                                                                                                                                            

  hsa05012: Parkinson's disease                         2.41E-03                                               UQCR10, NDUFS5, COX7B, COX8A, COX6B1, COX6A1, NDUFA1, ATP5H                                                                                                                                                                    

  hsa04932: Non-alcoholic fatty liver disease (NAFLD)   1.36E-02                                               UQCR10, NDUFS5, COX7B, COX8A, COX6B1, COX6A1, NDUFA1                                                                                                                                                                           

  hsa04260: Cardiac muscle contraction                  1.62E-02                                               UQCR10, COX7B, COX8A, COX6B1, COX6A1                                                                                                                                                                                           

  hsa03008: Ribosome biogenesis in eukaryotes           2.64E-02                                               SNORD3A, SNORD3C, SNORD3B-1, SNORD3B-2, NOP10                                                                                                                                                                                  

  Up                                                    BIOCARTA\                                              1.48E-02                                                                                                                                                                                                                       EIF4G2, PABPC1
                                                        h_eif4Pathway: Regulation of eIF4e and p70 S6 Kinase                                                                                                                                                                                                                                  
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

KEGG, Kyoto encyclopedia of genes and genomes.

PPI network construction
------------------------

After mapping the DEGs into the PPI data, a DEG-related PPI network was constructed ([Fig. 2A](#fig-2){ref-type="fig"}), including 92 nodes (86 downregulated and six upregulated) and 291 edges (interaction relationships, such as EIF4G2-PABPC1, SOD1-ATP5H) ([Supplemental Information 4](#supp-9){ref-type="supplementary-material"}). After calculating the degree, PABPC1 (degree = 15), ATP5H (degree = 11) and SOD1 (degree = 8) were suggested to be hub genes ([Fig. 2B](#fig-2){ref-type="fig"}).

![Protein--protein interaction network to screen crucial genes.\
(A) Protein--protein interaction network of differentially expressed genes between human lung epithelial cell Beas-2B exposed to amorphous silica nanoparticles or not. Downregulated genes were indicated as orange and upregulated genes were in green. (B) Proteins rank according their interaction pairs in the protein--protein interaction network.](peerj-07-6455-g002){#fig-2}

Following cluster analysis using the MCODE algorithm, three significant modules were obtained ([Fig. 3](#fig-3){ref-type="fig"}). Function enrichment analysis showed that ATP5H was included in module 3 and participated in Oxidative phosphorylation pathway ([Table 3](#table-3){ref-type="table"}).

![Modules obtained from PPI network.\
Orange, downregulated genes; green, upregulated genes. (A) Module 1; (B) module 2; (C) module 3.](peerj-07-6455-g003){#fig-3}
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###### KEGG pathway enrichment analysis for DEGs in modules.

![](peerj-07-6455-g008)

  Module   Term                                     *P*-value   Genes
  -------- ---------------------------------------- ----------- --------------------------------------------------------------------------
  1        hsa03010: Ribosome                       8.25E-17    RPS28, RPL41, RPS29, RPS15, RPL26, RPS4Y1, RPS13, RPS15A, RPL24, RPS5
  2        hsa05322: Systemic lupus erythematosus   9.23E-09    HIST1H2BO, HIST1H2BB, HIST1H2BK, HIST2H2AC, HIST1H3B, HIST1H2AM, HIST3H3
  3        hsa05012: Parkinson's disease            5.44E-12    NDUFS5, UQCR10, COX8A, COX7B, COX6B1, COX6A1, NDUFA1, ATP5H
           hsa00190: Oxidative phosphorylation      6.08E-12    NDUFS5, UQCR10, COX8A, COX7B, COX6B1, COX6A1, NDUFA1, ATP5H
           hsa05010: Alzheimer's disease            3.06E-11    NDUFS5, UQCR10, COX8A, COX7B, COX6B1, COX6A1, NDUFA1, ATP5H
           hsa05016: Huntington's disease           6.21E-11    NDUFS5, UQCR10, COX8A, COX7B, COX6B1, COX6A1, NDUFA1, ATP5H
           hsa04260: Cardiac muscle contraction     1.73E-06    UQCR10, COX8A, COX7B, COX6B1, COX6A1

**Note:**

DEGs, differentially expressed genes; KEGG, Kyoto encyclopedia of genes and genomes.

miRNA--mRNA interaction network
-------------------------------

A total of 18,896 target genes were predicted for the 41 DE-miRNAs by using the miRWalk database, 130 of which (including 124 downregulated and six upregulated) were found to be shared with the DEGs. Then, a miRNA--mRNA interaction network was constructed by using the 130 target genes and their corresponding 24 miRNAs, resulting in 1,615 and 17 interrelationship pairs for the 18 upregulated miRNAs and six downregulated miRNAs, respectively ([Fig. 4](#fig-4){ref-type="fig"}).

![A miRNA-gene interaction network.\
Blue diamond, upregulated miRNAs; yellow diamond, downregulated miRNAs; red oval, downregulated differentially expressed genes; green, upregulated differentially expressed genes.](peerj-07-6455-g004){#fig-4}

Function enrichment analysis also demonstrated these 130 target genes were involved in GO terms of response to reactive oxygen species (hsa-miR-3155b/3648/4522/4523/4533/4634/4734/572/661/933/1470-SOD1), and translational initiation (miR-5095/548ai/622/4521-EIF4G2, miR-4521-PABPC1) ([Table 4](#table-4){ref-type="table"}) and KEGG pathways of Oxidative phosphorylation (hsa-miR-1976/3155/3648/4461/4522/4523/4533/4634/4734/572/661/933-ATP5H) ([Table 5](#table-5){ref-type="table"}).
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###### Gene ontology (GO) biological process terms analysis for DEGs in miRNA--mRNA regulatory network.
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![](peerj-07-6455-g010)

  Term                                                                                                    *P*-value   Genes
  ------------------------------------------------------------------------------------------------------- ----------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  GO: 0006334∼nucleosome assembly                                                                         1.02E-17    HIST1H2BB, HIST1H3J, HIST1H4L, HIST1H1E, HIST1H1C, HIST1H2BF, HIST1H2BO, HIST1H2BK, HIST1H4B, HIST1H2BI, HIST1H3A, HIST1H4E, HIST1H3B, HIST1H3D, HIST1H4C, HIST1H4D, HIST1H3F, HIST3H3
  GO: 0051290∼protein heterotetramerization                                                               1.02E-16    HIST1H3J, HIST1H4L, XRCC6, ANXA2, HIST1H4B, HIST1H3A, HIST1H4E, HIST1H3B, HIST1H4C, HIST1H3D, HIST1H4D, HIST3H3, HIST1H3F
  GO: 0032200∼telomere organization                                                                       1.63E-13    HIST1H3J, HIST1H4L, HIST1H4B, HIST1H3A, HIST1H3B, HIST1H4E, HIST1H3D, HIST1H4C, HIST1H4D, HIST1H3F
  GO: 0045815∼positive regulation of gene expression, epigenetic                                          6.38E-13    HIST1H3J, HIST1H4L, POLR2L, POLR2K, HIST1H4B, HIST1H3A, HIST1H3B, HIST1H4E, HIST1H3D, HIST1H4C, HIST1H4D, HIST1H3F
  GO: 0006335∼DNA replication-dependent nucleosome assembly                                               9.45E-13    HIST1H3J, HIST1H4L, HIST1H4B, HIST1H3A, HIST1H3B, HIST1H4E, HIST1H3D, HIST1H4C, HIST1H4D, HIST1H3F
  GO: 0000183∼chromatin silencing at rDNA                                                                 4.07E-12    HIST1H3J, HIST1H4L, HIST1H4B, HIST1H3A, HIST1H3B, HIST1H4E, HIST1H3D, HIST1H4C, HIST1H4D, HIST1H3F
  GO: 0031047∼gene silencing by RNA                                                                       2.43E-11    HIST1H3J, HIST1H4L, POLR2L, POLR2K, HIST1H4B, HIST1H3A, HIST1H4E, HIST1H3B, HIST1H4C, HIST1H3D, HIST1H4D, PABPC1, HIST1H3F
  GO: 0045814∼negative regulation of gene expression, epigenetic                                          7.57E-11    HIST1H3J, HIST1H4L, HIST1H4B, HIST1H3A, HIST1H3B, HIST1H4E, HIST1H3D, HIST1H4C, HIST1H4D, HIST1H3F
  GO: 0044267∼cellular protein metabolic process                                                          8.57E-10    HIST1H3J, HIST1H4L, HIST1H4B, TGFBI, HIST1H3A, HIST1H3B, HIST1H4E, HIST1H3D, HIST1H4C, HIST1H4D, HIST1H3F, B2M
  GO: 0006413∼translational initiation                                                                    4.23E-09    EIF4G2, RPS28, RPS29, RPL41, RPS15, RPL26, RPS13, RPS15A, RPS4Y1, RPL24, PABPC1, RPS5
  GO: 0098609∼cell-cell adhesion                                                                          9.43E-09    HIST1H3J, CHMP5, PDLIM1, EEF2, RPL24, SFN, ANXA2, EIF4G2, KRT18, HIST1H3A, HIST1H3B, HIST1H3D, CNN2, HIST1H3F, ENO1
  GO: 0000184∼nuclear-transcribed mRNA catabolic process, nonsense-mediated decay                         1.42E-08    RPS28, RPS29, RPL41, RPS15, RPL26, RPS13, RPS15A, RPS4Y1, RPL24, PABPC1, RPS5
  GO: 0006614∼SRP-dependent cotranslational protein targeting to membrane                                 2.47E-08    RPS28, RPS29, RPL41, RPS15, RPL26, RPS13, RPS15A, RPS4Y1, RPL24, RPS5
  GO: 0019083∼viral transcription                                                                         1.14E-07    RPS28, RPS29, RPL41, RPS15, RPL26, RPS13, RPS15A, RPS4Y1, RPL24, RPS5
  GO: 0006303∼double-strand break repair via nonhomologous end joining                                    3.36E-07    HIST1H4L, HIST1H4B, XRCC6, HIST1H4E, BABAM1, HIST1H4C, HIST1H4D, HIST3H3
  GO: 0016233∼telomere capping                                                                            5.42E-07    HIST1H4L, HIST1H4B, HIST1H4E, HIST1H4C, HIST1H4D, HIST3H3
  GO: 0060968∼regulation of gene silencing                                                                8.14E-07    HIST1H3J, HIST1H3A, HIST1H3B, HIST1H3D, HIST1H3F
  GO: 0006364∼rRNA processing                                                                             3.38E-06    RPS28, RPS29, RPL41, RRP36, RPS15, RPL26, RPS13, RPS15A, RPS4Y1, RPL24, RPS5
  GO: 0045653∼negative regulation of megakaryocyte differentiation                                        7.26E-06    HIST1H4L, HIST1H4B, HIST1H4E, HIST1H4C, HIST1H4D
  GO: 0034080∼CENP-A containing nucleosome assembly                                                       1.38E-05    HIST1H4L, HIST1H4B, HIST1H4E, CENPW, HIST1H4C, HIST1H4D
  GO: 0006412∼translation                                                                                 1.48E-05    RPS28, RPS29, RPL41, RPS15, RPL26, RPS13, RPS15A, RPS4Y1, RPL24, MRPS7, RPS5
  GO: 0006342∼chromatin silencing                                                                         1.73E-05    HIST1H2AB, HIST2H2AB, HIST2H2AA4, HIST2H2AC, HIST1H2AE, HIST1H2AM
  GO: 0006336∼DNA replication-independent nucleosome assembly                                             3.39E-05    HIST1H4L, HIST1H4B, HIST1H4E, HIST1H4C, HIST1H4D
  GO: 0006352∼DNA-templated transcription, initiation                                                     1.26E-04    HIST1H4L, HIST1H4B, HIST1H4E, HIST1H4C, HIST1H4D
  GO: 1904837∼beta-catenin-TCF complex assembly                                                           2.55E-04    HIST1H4L, HIST1H4B, HIST1H4E, HIST1H4C, HIST1H4D
  GO: 0000028∼ribosomal small subunit assembly                                                            3.25E-04    RPS28, RPS15, MRPS7, RPS5
  GO: 0006123∼mitochondrial electron transport, cytochrome c to oxygen                                    3.80E-04    COX7B, COX8A, COX6B1, COX6A1
  GO: 0045727∼positive regulation of translation                                                          5.72E-04    EIF4G2, EEF2, QARS, PABPC1, THBS1
  GO: 1902600∼hydrogen ion transmembrane transport                                                        9.75E-04    UQCR10, COX7B, COX8A, COX6B1, COX6A1
  GO: 0043154∼negative regulation of cysteine-type endopeptidase activity involved in apoptotic process   1.55E-03    PRDX5, SFN, THBS1, IFI6, DHCR24
  GO: 0019731∼antibacterial humoral response                                                              3.90E-03    HIST1H2BK, HIST1H2BF, HIST1H2BI, B2M
  GO: 0042274∼ribosomal small subunit biogenesis                                                          5.79E-03    RPS28, RRP36, RPS15
  GO: 0002227∼innate immune response in mucosa                                                            1.39E-02    HIST1H2BK, HIST1H2BF, HIST1H2BI
  GO: 0050434∼positive regulation of viral transcription                                                  1.84E-02    POLR2L, POLR2K, SUPT4H1
  GO: 0050830∼defense response to Gram-positive bacterium                                                 2.35E-02    HIST1H2BK, HIST1H2BF, HIST1H2BI, B2M
  GO: 0006368∼transcription elongation from RNA polymerase II promoter                                    2.42E-02    POLR2L, POLR2K, ELOF1, SUPT4H1
  GO: 0033489∼cholesterol biosynthetic process via desmosterol                                            2.85E-02    DHCR7, DHCR24
  GO: 0033490∼cholesterol biosynthetic process via lathosterol                                            2.85E-02    DHCR7, DHCR24
  GO: 0007568∼aging                                                                                       3.15E-02    CCL2, EEF2, SOD1, NQO1, APEX1
  GO: 0000302∼response to reactive oxygen species                                                         3.21E-02    TXN, PRDX5, SOD1
  GO: 0001895∼retina homeostasis                                                                          3.36E-02    ACTG1, SOD1, B2M
  GO: 0002576∼platelet degranulation                                                                      3.84E-02    PSAP, THBS1, SOD1, SRGN
  GO: 0043488∼regulation of mRNA stability                                                                3.84E-02    PSMB3, HSPA1B, PABPC1, APEX1
  GO: 0045471∼response to ethanol                                                                         4.03E-02    CCL2, EEF2, SOD1, NQO1
  GO: 0006356∼regulation of transcription from RNA polymerase I promoter                                  4.25E-02    POLR2L, POLR2K
  GO: 0098532∼histone H3-K27 trimethylation                                                               4.25E-02    HIST1H1E, HIST1H1C
  GO: 0007596∼blood coagulation                                                                           4.41E-02    HIST1H3J, HIST1H3A, HIST1H3B, HIST1H3D, HIST1H3F
  GO: 0009615∼response to virus                                                                           4.52E-02    IFITM2, IFITM3, RPS15A, ENO1
  GO: 0043066∼negative regulation of apoptotic process                                                    4.65E-02    KRT18, PLK2, PLK1, TMBIM4, PRDX5, THBS1, NQO1, DHCR24
  GO: 1900121∼negative regulation of receptor binding                                                     4.94E-02    ANXA2, B2M
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###### KEGG pathway enrichment analysis for DEGs in miRNA--mRNA regulatory network.
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  Term                                                  *P*-value   Genes
  ----------------------------------------------------- ----------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  hsa05322: Systemic lupus erythematosus                5.48E-18    HIST1H2AB, HIST1H2BB, HIST1H3J, HIST1H4L, HIST2H2AA4, HIST1H2BF, HIST1H2AE, HIST1H2BO, HIST2H2AB, HIST1H2BK, HIST1H4B, HIST2H2AC, HIST1H2BI, HIST1H3A, HIST1H4E, HIST1H3B, HIST1H3D, HIST1H4C, HIST1H4D, HIST1H3F, HIST1H2AM, HIST3H3
  hsa05034: Alcoholism                                  2.00E-15    HIST1H2AB, HIST1H2BB, HIST1H3J, HIST1H4L, HIST2H2AA4, HIST1H2BF, HIST1H2AE, HIST1H2BO, HIST2H2AB, HIST1H2BK, HIST1H4B, HIST2H2AC, HIST1H2BI, HIST1H3A, HIST1H4E, HIST1H3B, HIST1H3D, HIST1H4C, HIST1H4D, HIST1H3F, HIST1H2AM, HIST3H3
  hsa03010: Ribosome                                    6.90E-06    RPS28, RPS29, RPL41, RPS15, RPL26, RPS13, RPS15A, RPS4Y1, RPL24, MRPS7, RPS5
  hsa05016: Huntington's disease                        6.46E-04    UQCR10, NDUFS5, POLR2L, POLR2K, COX7B, COX8A, COX6B1, COX6A1, SOD1, ATP5H
  hsa05203: Viral carcinogenesis                        1.03E-03    HIST1H2BO, HIST1H2BB, HIST1H4L, HIST1H2BK, HIST1H2BF, HIST1H4B, HIST1H2BI, HIST1H4E, HIST1H4C, HIST1H4D
  hsa00190: Oxidative phosphorylation                   1.36E-03    UQCR10, NDUFS5, ATP6V0E1, COX7B, COX8A, COX6B1, COX6A1, ATP5H
  hsa05010: Alzheimer's disease                         5.06E-03    UQCR10, NDUFS5, COX7B, COX8A, COX6B1, COX6A1, PSENEN, ATP5H
  hsa05012: Parkinson's disease                         8.75E-03    UQCR10, NDUFS5, COX7B, COX8A, COX6B1, COX6A1, ATP5H
  hsa04260: Cardiac muscle contraction                  1.45E-02    UQCR10, COX7B, COX8A, COX6B1, COX6A1
  hsa04932: Non-alcoholic fatty liver disease (NAFLD)   4.12E-02    UQCR10, NDUFS5, COX7B, COX8A, COX6B1, COX6A1

Discussion
==========

After PPI hub genes and module analysis as well as miRNA target gene prediction, our present study preliminarily suggests downregulated ATP5H, SOD1 and upregulated EIF4G2, PABPC1 may be especially important genes involved in amorphous SiNPs-mediated tumor initiation. EIF4G2 and PABPC1 may be involved in the progression of cancer by affecting translational initiation, while SOD1 and ATP5H may participate in carcinogenesis via influencing oxidative stress and oxidative phosphorylation. Although genes were not similar, these enriched pathways seemed to be in line with the study of [@ref-12], further indicating these biological processes may be crucial.

Recently, accumulating evidence has indicated exposure to amorphous SiNPs induces oxidative stress in cells or organs ([@ref-13]; [@ref-32]; [@ref-21]). For example, [@ref-15] incubated the erythrocytes with SiNPs and found the oxidative damage biomarker malondialdehyde was significantly increased, while the activity of antioxidant superoxide dismutase (SOD) was decreased. [@ref-4] showed exposure of SiNPs to macrophages elicited a greater oxidative stress than was assessed from heme oxygenase-1 induction and ROS production. [@ref-21] observed intraperitoneal administration of SiNPs induced significantly increased lipid peroxidation in the lung, liver, kidney and brain of mice, displaying reduced SOD and catalase activities. Consistent with these studies, our study also found anti-oxidative gene SOD1 was significantly downregulated after SiNPs treatment. The increased oxidative stress was reported to induce the switch of glucose metabolism from oxidative phosphorylation to aerobic glycolysis (the Warburg Effect) to promote excessive proliferation and growth of cells, leading to the development and progression of cancer ([@ref-22]; [@ref-20]). ATP synthase is an enzyme to be responsible for the synthesis of abundant ATP in oxidative phosphorylation process. The expression of ATP synthase may be reduced due to the decreased oxidative phosphorylation. As expected, [@ref-8] found significantly reduced levels of ATP Synthase Subunit ATP5F1A was correlated with earlier-onset prostate cancer. [@ref-28] used the two-dimensional gel electrophoresis data to demonstrate the expression and activity of ATP synthase were lower in 5-FU-resistant cells compared with parent cancer cells. Inhibition of ATP synthase by oligomycin A or siRNA transfection strongly antagonized 5-FU-induced suppression of cell proliferation and increased cell viability. Similarly, the study of [@ref-29] indicated loss of ATP5H conferred a stem-like, invasive phenotype to tumor cells as well as multimodal resistance to immunotherapy, chemotherapy and radiotherapy. Also, reduced levels of ATP synthase were associated with poor prognosis in cancer patients ([@ref-29]). In agreement with these studies, we also found ATP5H could interact with SOD1 and was downregulated in malignant transformation after SiNPs treatment.

In accordance with our hypothesis that the increased oxidative stress and aerobic glycolysis may accelerate the cell proliferation, we also found translational initiation was abnormally activated in human lung epithelial cells after SiNPs exposure, which may, on one hand, promote cell division and on the other hand, maintains cell survival ([@ref-25]). Translation process requires the protein complex known as eukaryotic initiation factor 4F (eIF4F) which consists of cap-binding protein eIF4E, scaffolding protein eIF4G and ATP-dependent RNA helicase eIF4A ([@ref-11]). Hereby, the expression of translation protein related genes may be upregulated in malignant transformation, which have been confirmed in several cancers because downregulation of eIF4GII was reported to decrease cell proliferation, but induces cellular senescence ([@ref-6]; [@ref-33]). During translation process in eukaryotic cells, nonsense mutations (premature stop codon) may be present, which disrupts production of full-length, functional proteins (such as tumor suppressor gene p53) and thus may induce the development of various diseases, including cancers ([@ref-16]). Nonsense-mediated mRNA decay (NMD) represents a surveillance mechanism that eliminates transcripts with nonsense mutations and prevents cancer development. In contrast, inhibition of NMD may result in the initiation of cancer ([@ref-2]). Recent studies showed PABPC1 can interact with eIF4G to inhibit NMD ([@ref-7]; [@ref-23]). Thus, the upregulation of PABPC1 may be one underlying reason for tumor formation. This hypothesis has been demonstrated in the gastric carcinoma ([@ref-38]) and hepatocellular carcinoma ([@ref-37]) samples. As expected, our present study also demonstrated SiNPs may induce the tumorigenesis of Beas-2B cells by upregulating EIF4G2 and PABPC1. These two genes could interact with each other.

More interestingly, our study showed the downregulation of ATP5H and SOD1 may be resulted from the upregulation of their common upstream miR-3648/572/661, while the downregulated miR-4521 may lead to the upregulation of the transcription of EIF4G2 and PABPC1. Although all these were the potential mechanisms firstly obtained for the carcinogenicity of amorphous SiNPs, recent studies on the miR-3648/572/661 and miR-4521 may indirectly demonstrate their importance in cancer development. For example, [@ref-26] demonstrated overexpression of miR-3648 promoted the growth of HeLa cells, while opposite results were obtained when miR-3648 was inhibited by antagomir. The mechanism of miR-3648 for cancer progression was to suppress the expression of a tumor suppressor gene adenomatous polyposis coli 2. miR-572 was also found to be highly expressed in human ovarian cancer tissues and cell lines. Ectopic overexpression of miR-572 promoted ovarian cancer cell proliferation and cell cycle progression in vitro and tumorigenicity in vivo by inhibiting its direct target suppressor of cytokine signaling 1 and cyclin-dependent kinase inhibitor 1A (p21KIP). Kaplan--Meir analysis indicated that high level expression of miR-572 was associated with poorer overall survival ([@ref-36]). miR-572 also can induce proliferation, invasion and inhibit apoptosis of nasopharyngeal carcinoma cells by targeting protein phosphatase 2 regulatory subunit Bgamma ([@ref-35]). miR-661 was observed to be upregulated in non-small cell lung cancer (NSCLC) tissues as compared to paired adjacent tissues. Furthermore, miR-661 promoted proliferation, migration and metastasis of NSCLC by regulating RB1 and mediating epithelial-mesenchymal transition process in NSCLC ([@ref-19]). [@ref-34] observed miR-4521 was downregulated in chemotherapy-resistant renal cell carcinoma. However, the studies on miR-3648/572/661 and miR-4521 remains rare and their regulatory relationship with our predicted target genes have not been investigated.

However, there are some limitations in this study. First, this is a preliminary study to identify the potential carcinogenic mechanisms of amorphous SiNPs. Additional wet experiments are necessary to confirm the expressions of identified genes and miRNAs (i.e., PCR), their interaction relationships (i.e., dual-luciferase, overexpression or knockout in vitro and in vivo) as well as the influence on the cell proliferation, apoptosis, migration and invasion. Second, our obtained miRNAs from the transcriptome array may be pre-miRNAs. Thus, further miRNA microarray (such as Affymetrix GeneChip miRNA v4) or sequencing analysis is essential to screen more crucial mature miRNAs.

Conclusion
==========

Our findings reveal amorphous SiNPs may exert a carcinogenic effect by targeted regulating of miR-3648/572/661 and miR-4521 followed by influencing their downstream target genes (ATP5H/SOD1 and EIF4G2/PABPC1, respectively). These target genes may be involved in cancer development by promoting oxidative stress, translational initiation, while also inhibiting oxidative phosphorylation and NMD. Accordingly, the four miRNAs and their target genes may be underlying biomarkers for prediction of carcinogenesis when exposed to SiNPs and potentially other targets for cancer treatment.
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